-
Markets
athexgroup.grAthens Exchange GroupRead moreTogether for a unified, stronger European capital market.
-
Equities
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Commodities
- Overview
- Agricultural quotes
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Container Freight Futures
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
26 Jan 2026 22:00 CET
Issuer
INVENTIVA SA
Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux.
Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2025:
- Cash: € 526,751.56
- Number of shares: 58,515
- Number of executions on buy side on semester: 2,332
- Number of executions on sell side on semester: 2,741
- Traded volume on buy side on semester: 550,198 shares for € 2,093,559.19
- Traded volume on sell side on semester: 576,215 shares for € 2,189,327.66
At the last half-year report as of 30 June 2025 the following resources were available in the liquidity account:
- Cash: € 428,212.57
- Number of shares: 84,532
- Number of executions on buy side on semester: 1,642
- Number of executions on sell side on semester: 1,878
- Traded volume on buy side on semester: 267,584 shares for € 744,692.94
- Traded volume on sell side on semester: 296,504 shares for € 819,771.51
When the contract was initially implemented, the following resources were included in the liquidity account:
- Cash: € 163,510.42
- Number of shares: 34,063
| Buy Side | Sell Side | ||||||
| Number of executions | Number of shares | Traded volume in EUR | Number of executions | Number of shares | Traded volume in EUR | ||
| Total | 2,332 | 550,198 | 2,093,559.19 | 2,741 | 576,215 | 2,189,327.66 | |
| 07/01/2025 | 14 | 2,613 | 6,846.06 | 10 | 1,236 | 3,275.40 | |
| 07/02/2025 | 18 | 3,372 | 8,699.76 | - | - | - | |
| 07/03/2025 | 9 | 1,501 | 3,977.65 | 49 | 8,037 | 21,378.42 | |
| 07/04/2025 | 17 | 2,999 | 7,917.36 | 2 | 500 | 1,325.00 | |
| 07/07/2025 | 21 | 1,516 | 4,017.40 | 19 | 3,342 | 8,923.14 | |
| 07/08/2025 | 4 | 837 | 2,293.38 | 37 | 5,720 | 15,730.00 | |
| 07/09/2025 | 10 | 1,750 | 4,830.00 | 21 | 2,500 | 6,975.00 | |
| 07/10/2025 | 5 | 778 | 2,155.06 | 10 | 1,001 | 2,782.78 | |
| 07/11/2025 | 8 | 1,607 | 4,467.46 | 16 | 1,999 | 5,597.20 | |
| 07/14/2025 | 18 | 2,878 | 7,885.72 | 5 | 550 | 1,518.00 | |
| 07/15/2025 | 3 | 252 | 690.48 | 20 | 2,500 | 6,900.00 | |
| 07/16/2025 | 7 | 1,498 | 4,149.46 | 13 | 1,977 | 5,515.83 | |
| 07/17/2025 | 1 | 250 | 695.00 | 10 | 1,023 | 2,843.94 | |
| 07/18/2025 | 8 | 1,000 | 2,760.00 | 4 | 240 | 669.60 | |
| 07/21/2025 | 15 | 2,270 | 6,197.10 | 1 | 250 | 685.00 | |
| 07/22/2025 | 6 | 1,000 | 2,750.00 | 27 | 3,760 | 10,377.60 | |
| 07/23/2025 | 33 | 5,730 | 15,757.50 | 35 | 6,450 | 17,995.50 | |
| 07/24/2025 | 8 | 1,750 | 4,742.50 | - | - | - | |
| 07/25/2025 | - | - | - | 4 | 1,000 | 2,780.00 | |
| 07/28/2025 | 21 | 4,750 | 13,347.50 | 42 | 7,753 | 22,173.58 | |
| 07/29/2025 | 2 | 250 | 725.00 | 75 | 11,154 | 32,346.60 | |
| 07/30/2025 | 27 | 4,531 | 12,958.66 | 10 | 1,615 | 4,731.95 | |
| 07/31/2025 | 20 | 3,969 | 11,192.58 | 25 | 4,750 | 13,585.00 | |
| 08/01/2025 | 17 | 2,750 | 7,755.00 | 7 | 1,251 | 3,590.37 | |
| 08/04/2025 | 11 | 2,500 | 6,950.00 | 5 | 1,031 | 2,876.49 | |
| 08/05/2025 | 13 | 1,750 | 4,935.00 | 12 | 1,719 | 4,864.77 | |
| 08/06/2025 | 11 | 1,984 | 5,555.20 | 19 | 3,539 | 10,050.76 | |
| 08/07/2025 | 21 | 3,000 | 8,700.00 | 22 | 3,411 | 9,994.23 | |
| 08/08/2025 | 12 | 2,067 | 5,932.29 | 21 | 2,049 | 5,962.59 | |
| 08/11/2025 | 10 | 2,000 | 5,840.00 | 21 | 2,250 | 6,592.50 | |
| 08/12/2025 | 2 | 279 | 825.84 | 28 | 3,750 | 11,137.50 | |
| 08/13/2025 | 22 | 2,901 | 8,993.10 | 66 | 9,750 | 30,615.00 | |
| 08/14/2025 | 4 | 750 | 2,527.50 | 65 | 10,999 | 37,396.60 | |
| 08/15/2025 | 18 | 3,750 | 12,862.50 | 14 | 2,050 | 7,154.50 | |
| 08/18/2025 | 3 | 750 | 2,535.00 | 34 | 5,700 | 20,406.00 | |
| 08/19/2025 | 16 | 3,250 | 12,382.50 | 67 | 9,000 | 34,740.00 | |
| 08/20/2025 | 11 | 2,500 | 9,650.00 | 14 | 3,040 | 11,825.60 | |
| 08/21/2025 | 29 | 4,108 | 15,651.48 | 16 | 3,460 | 13,390.20 | |
| 08/22/2025 | 14 | 2,992 | 11,459.36 | 10 | 1,751 | 6,811.39 | |
| 08/25/2025 | 7 | 1,750 | 6,772.50 | 39 | 6,750 | 27,067.50 | |
| 08/26/2025 | 14 | 2,750 | 11,110.00 | 19 | 3,250 | 13,292.50 | |
| 08/27/2025 | - | - | - | 75 | 12,250 | 54,145.00 | |
| 08/28/2025 | 20 | 4,000 | 19,320.00 | 38 | 7,000 | 34,440.00 | |
| 08/29/2025 | 28 | 6,250 | 29,500.00 | 40 | 5,750 | 27,887.50 | |
| 09/01/2025 | 36 | 6,750 | 31,792.50 | 10 | 1,500 | 7,560.00 | |
| 09/02/2025 | 16 | 3,000 | 13,260.00 | 10 | 2,250 | 10,125.00 | |
| 09/03/2025 | - | - | - | 27 | 5,000 | 23,400.00 | |
| 09/04/2025 | 34 | 13,000 | 58,760.00 | - | - | - | |
| 09/05/2025 | 6 | 3,955 | 17,599.75 | 2 | 2,000 | 9,000.00 | |
| 09/08/2025 | 27 | 12,000 | 52,320.00 | 7 | 10,000 | 44,000.00 | |
| 09/09/2025 | 1 | 2,000 | 8,900.00 | 8 | 10,000 | 45,500.00 | |
| 09/10/2025 | - | - | - | 3 | 4,000 | 18,600.00 | |
| 09/11/2025 | - | - | - | 3 | 1,000 | 4,750.00 | |
| 09/12/2025 | 4 | 750 | 3,487.50 | - | - | - | |
| 09/15/2025 | 3 | 2,500 | 11,300.00 | 2 | 250 | 1,195.00 | |
| 09/16/2025 | 4 | 3,500 | 15,575.00 | 2 | 1,000 | 4,500.00 | |
| 09/17/2025 | 6 | 7,000 | 30,170.00 | 5 | 4,000 | 17,360.00 | |
| 09/18/2025 | - | - | - | 12 | 3,000 | 13,560.00 | |
| 09/19/2025 | - | - | - | 4 | 2,000 | 9,240.00 | |
| 09/22/2025 | 16 | 2,345 | 10,904.25 | 18 | 3,250 | 15,307.50 | |
| 09/23/2025 | 29 | 5,750 | 27,025.00 | 32 | 6,500 | 30,810.00 | |
| 09/24/2025 | 30 | 5,278 | 24,912.16 | 16 | 3,500 | 16,765.00 | |
| 09/25/2025 | - | - | - | 34 | 6,955 | 34,427.25 | |
| 09/26/2025 | 31 | 6,750 | 33,075.00 | 33 | 6,250 | 31,000.00 | |
| 09/29/2025 | 40 | 9,500 | 46,930.00 | 35 | 7,000 | 35,280.00 | |
| 09/30/2025 | 39 | 8,000 | 38,560.00 | 20 | 3,750 | 18,337.50 | |
| 10/01/2025 | 14 | 2,751 | 13,554.95 | 33 | 6,250 | 31,270.00 | |
| 10/02/2025 | 12 | 2,750 | 13,970.00 | 38 | 7,335 | 37,921.95 | |
| 10/03/2025 | 37 | 8,000 | 42,640.00 | 41 | 6,250 | 33,625.00 | |
| 10/06/2025 | 47 | 9,250 | 47,452.50 | 13 | 1,500 | 7,755.00 | |
| 10/07/2025 | 40 | 8,249 | 41,162.51 | 24 | 3,750 | 19,387.50 | |
| 10/08/2025 | 47 | 8,722 | 40,470.08 | 20 | 3,047 | 14,503.72 | |
| 10/09/2025 | 49 | 10,900 | 46,216.00 | 35 | 6,000 | 25,620.00 | |
| 10/10/2025 | 41 | 9,250 | 37,185.00 | 27 | 4,750 | 19,380.00 | |
| 10/13/2025 | 52 | 9,900 | 38,412.00 | 12 | 2,750 | 10,917.50 | |
| 10/14/2025 | 30 | 6,500 | 23,855.00 | 56 | 12,000 | 46,200.00 | |
| 10/15/2025 | 37 | 8,000 | 30,880.00 | 13 | 3,000 | 11,760.00 | |
| 10/16/2025 | 27 | 5,750 | 20,757.50 | 26 | 5,069 | 18,856.68 | |
| 10/17/2025 | 30 | 6,250 | 21,625.00 | 21 | 4,000 | 13,960.00 | |
| 10/20/2025 | 30 | 6,750 | 22,545.00 | 13 | 3,250 | 10,985.00 | |
| 10/21/2025 | 15 | 3,500 | 11,550.00 | 16 | 2,750 | 9,212.50 | |
| 10/22/2025 | 29 | 6,600 | 21,054.00 | 9 | 2,000 | 6,400.00 | |
| 10/23/2025 | 23 | 4,899 | 15,039.93 | 19 | 4,500 | 13,950.00 | |
| 10/24/2025 | 18 | 4,000 | 12,280.00 | 17 | 3,474 | 10,977.84 | |
| 10/27/2025 | 13 | 3,000 | 9,210.00 | 44 | 7,500 | 23,325.00 | |
| 10/28/2025 | 13 | 3,250 | 10,562.50 | 72 | 13,526 | 44,500.54 | |
| 10/29/2025 | 52 | 12,000 | 39,600.00 | 95 | 20,181 | 74,669.70 | |
| 10/30/2025 | 47 | 8,755 | 30,467.40 | 3 | 750 | 2,625.00 | |
| 10/31/2025 | 5 | 1,250 | 4,500.00 | 33 | 6,750 | 24,435.00 | |
| 11/03/2025 | 35 | 7,295 | 26,043.15 | 26 | 4,574 | 16,740.84 | |
| 11/04/2025 | 21 | 3,005 | 10,547.55 | 34 | 7,177 | 25,837.20 | |
| 11/05/2025 | 26 | 4,606 | 16,489.48 | 9 | 2,250 | 8,190.00 | |
| 11/06/2025 | 12 | 2,050 | 7,646.50 | 39 | 7,500 | 28,350.00 | |
| 11/07/2025 | 24 | 5,344 | 19,398.72 | 5 | 1,250 | 4,650.00 | |
| 11/10/2025 | 39 | 8,495 | 29,052.90 | 4 | 750 | 2,685.00 | |
| 11/11/2025 | 12 | 2,250 | 7,312.50 | - | - | - | |
| 11/12/2025 | 6 | 1,500 | 5,040.00 | 26 | 4,500 | 15,210.00 | |
| 11/13/2025 | 9 | 2,250 | 7,245.00 | 3 | 750 | 2,430.00 | |
| 11/14/2025 | 9 | 2,250 | 7,177.50 | 12 | 2,500 | 8,325.00 | |
| 11/17/2025 | 10 | 2,500 | 8,575.00 | 46 | 8,000 | 28,080.00 | |
| 11/18/2025 | 22 | 3,750 | 12,975.00 | 11 | 1,500 | 5,235.00 | |
| 11/19/2025 | 14 | 3,000 | 10,410.00 | 14 | 3,500 | 12,285.00 | |
| 11/20/2025 | 17 | 2,750 | 9,570.00 | 18 | 4,250 | 15,130.00 | |
| 11/21/2025 | 28 | 4,895 | 17,132.50 | 8 | 2,000 | 7,100.00 | |
| 11/24/2025 | 13 | 2,800 | 9,660.00 | 30 | 4,000 | 14,000.00 | |
| 11/25/2025 | 15 | 3,307 | 12,037.48 | 51 | 10,000 | 36,900.00 | |
| 11/26/2025 | 36 | 12,000 | 45,960.00 | 34 | 11,520 | 45,388.80 | |
| 11/27/2025 | 17 | 6,500 | 24,245.00 | 30 | 9,000 | 34,110.00 | |
| 11/28/2025 | 21 | 4,443 | 16,261.38 | 1 | 500 | 1,850.00 | |
| 12/01/2025 | 6 | 2,000 | 7,240.00 | 4 | 1,000 | 3,690.00 | |
| 12/02/2025 | 28 | 12,500 | 46,750.00 | 17 | 7,500 | 28,725.00 | |
| 12/03/2025 | 48 | 14,255 | 49,607.40 | - | - | - | |
| 12/04/2025 | 16 | 5,500 | 19,140.00 | 14 | 5,000 | 17,550.00 | |
| 12/05/2025 | 22 | 4,500 | 15,705.00 | 7 | 2,506 | 8,821.12 | |
| 12/08/2025 | 9 | 2,500 | 8,700.00 | 21 | 6,912 | 24,192.00 | |
| 12/09/2025 | 12 | 5,000 | 17,750.00 | 25 | 8,082 | 29,014.38 | |
| 12/10/2025 | 23 | 6,206 | 22,713.96 | 31 | 11,060 | 41,475.00 | |
| 12/11/2025 | 18 | 7,000 | 26,180.00 | 16 | 5,000 | 19,000.00 | |
| 12/12/2025 | 5 | 2,000 | 7,520.00 | 1 | 80 | 308.80 | |
| 12/15/2025 | 26 | 9,000 | 33,750.00 | 15 | 5,500 | 20,900.00 | |
| 12/16/2025 | 23 | 9,294 | 33,830.16 | 21 | 8,001 | 29,523.69 | |
| 12/17/2025 | 13 | 6,000 | 22,620.00 | 29 | 9,359 | 35,844.97 | |
| 12/18/2025 | 18 | 8,000 | 30,320.00 | 17 | 6,943 | 27,216.56 | |
| 12/19/2025 | 22 | 9,500 | 34,675.00 | 13 | 5,000 | 18,450.00 | |
| 12/22/2025 | 21 | 6,500 | 23,335.00 | 22 | 8,000 | 29,280.00 | |
| 12/23/2025 | 22 | 7,500 | 28,800.00 | 29 | 10,494 | 40,821.66 | |
| 12/24/2025 | 12 | 4,353 | 16,280.22 | 10 | 4,000 | 15,160.00 | |
| 12/29/2025 | 4 | 64 | 239.36 | 13 | 3,563 | 13,681.92 | |
| 12/30/2025 | 5 | 1,000 | 3,880.00 | 3 | 1,500 | 5,910.00 | |
| 12/31/2025 | 5 | 1,000 | 3,870.00 | 2 | 500 | 1,960.00 | |
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com
Contacts
| Inventiva Pascaline Clerc, PhD EVP, External and Corporate Affairs media@inventivapharma.com +1 202 499 8937 | ICR Healthcare Alexis Feinberg Media Relations inventivapr@icrhealthcare.com +1 203 939 2225 | ICR Healthcare Patricia L. Bank Investor Relations patti.bank@icrhealthcare.com +1 415 513 1284 |
Attachment
Source
INVENTIVA
Provider
GlobeNewswire
Company Name
INVENTIVA
ISIN
FR0013233012
Symbol
IVA
Market
Euronext